Evidence of VEGF expression in renal cell carcinoma (RCC)

Angiogenesis is a major driving factor in the pathogenesis of renal cell carcinoma (RCC). The angiogenic phenotype occurs as a result of the high incidence of von Hippel-Lindau tumor suppressor gene (VHL) loss, which leads to hypoxia-inducible factor (HIF) dysregulation and a subsequent increase in proangiogenic factors.^1,2 Thus, it would be expected that high vascular endothelial growth factor (VEGF) expression would be evident in RCC. Indeed, several investigators have confirmed this hypothesis by measuring VEGF expression either through mRNA or protein levels. VEGF expression was observed in the vast majority of RCCs, and several reports noted increased VEGF expression in tumor tissue compared with normal renal tissue.^3-8 Together, these data demonstrate that VEGF is a key mediator of angiogenesis in RCC.

Prevalence of VEGF-expressing tumors

A number of investigators have examined RCCs to see whether VEGF is highly expressed. Their methods include the measurement of VEGF mRNA expression, as well as the measurement of VEGF protein levels. The results of 6 clinical studies show that the vast majority of RCCs highly expressed VEGF, underscoring the critical role of VEGF and angiogenesis in RCC.^3-8

References:

1.

Rini BI, Small EJ. J Clin Oncol. 2005;23:1028-1043.

2.

Haase VH. Kidney Int. 2006;69:1302-1307.

3.

Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, Thelen P. Virchows Arch. 2001;439:645-652.

4.

Lee JS, Kim HS, Jung JJ, Park CS, Lee MC. J Surg Oncol. 2001;77:55-60.

5.

Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. J Urol. 2003;170:588-592.

6.

Nicol D, Hii SI, Walsh M, et al. J Urol. 1997;157:1482-1486.

7.

Takahashi A, Sasaki H, Kim SJ, et al. Cancer Res. 1994;54:4233-4237.

8.

Tomisawa M, Tokunaga T, Oshika Y, et al. Eur J Cancer. 1999;35:133-137.